Darolutamide is a formulation containing an androgen receptor (AR) antagonist with potential antineoplastic activity. Darolutamide binds to ARs in target tissues; subsequently, inhibiting androgen-induced receptor activation and facilitating the formation of inactive complexes that cannot translocate to the nucleus. This prevents binding to and transcription of AR-responsive genes that regulate prostate cancer cell proliferation. This ultimately leads to an inhibition of growth in AR-expressing prostate cancer cells.
Darolutamide is a nonsteroidal androgen receptor antagonist for the treatment of castrate-resistant, non-metastatic prostate cancer (nmCRPC). This condition occurs in the majority of patients with advanced prostate cancer who have been treated with androgen receptor antagonists. Though prior treatment for prostate cancer has been successful for these patients, cancer eventually progresses to become resistant to existing therapies. This warrants further treatment. The goal of treatment with darolutamide is to delay the progression of prostate cancer to metastatic disease, increasing the quality of life and life expectancy for those with advanced prostate cancer. Darolutamide was developed by Bayer HealthCare Pharmaceuticals Inc. and approved by the FDA on July 30th, 2019.
Mechanism of Action
The actions of androgens on androgen receptors (AR) potentiate the growth and survival of prostate cancer cells. Darolutamide competitively inhibits androgens from binding to their receptors, inhibiting AR nuclear translocation, as well as AR-mediated transcription. The end result of these processes is a decrease in prostate cancer cell proliferation and tumor size. Its main metabolite, keto-darolutamide, shows similar pharmacological activity to the parent drug, darolutamide. Darolutamide has been found to bind more tightly to the AR receptor than [apalutamide] and [enzalutamide], which are other androgen receptor antagonists. Darolutamide can act as a progesterone receptor (PR) antagonist in the laboratory setting with approximately 1% activity when compared to its actions at the androgen receptor. The clinical relevance is not known at this time.
Indications
- This drug is indicated for the treatment of patients diagnosed with non-metastatic and castrate-resistant prostate cancer.
- Nubeqa is indicated for the treatment of adult men with non-metastatic castration-resistant prostate cancer (nmCRPC) who are at risk of developing metastatic disease.
- Darolutamide is approved for use concurrently with a gonadotropin-releasing hormone (GnRH) agonist or antagonist or bilateral orchiectomy in the treatment of non-metastatic castration-resistant prostate cancer (nmCRPC) in men
- Darolutamide, through its downstream effects on cancer cell growth, treats castrate-resistant prostate cancer. It inhibits cancer cell growth and markedly lowers prostate-specific antigen (PSA) levels through potent androgen receptor antagonism.
- Darolutamide is an androgen receptor antagonist used for castration-resistant, non-metastatic prostate cancer and metastatic hormone-sensitive prostate cancer.
- Metastatic Hormone Sensitive Prostate Cancer
- Non-mestatatic castrate-resistant prostate cancer
Use in Cancer
Darolutamide is approved to treat:
- Prostate cancer. It is used in adults whose cancer:
- Has spread to other parts of the body and responds to treatment that lowers testosterone levels. It is used with docetaxel.
- Has not spread to other parts of the body and no longer responds to treatment that lowers testosterone levels.
Darolutamide is also being studied in the treatment of other types of cancer.
Contraindications
- excessive fat in the blood
- a low seizure threshold
- high blood pressure
- coronary artery disease
- seizures
- pregnancy
- chronic kidney disease stage 4 (severe)
- Child-Pugh class B liver impairment
Dosage
Strengths: 300 mg
Prostate Cancer
- 600 mg orally 2 times a day
- Patients receiving this drug should also receive a gonadotropin-releasing hormone (GnRH) analog concurrently or should have had a bilateral orchiectomy.
- For nonmetastatic castration-resistant prostate cancer (nmCRPC)
Renal Dose Adjustments
- Mild to moderate renal impairment (CrCl 30 to 89 mL/min): No adjustment recommended.
- Severe renal impairment (CrCl 15 to 29 mL/min) who are not receiving hemodialysis: 300 mg orally 2 times a da
- End-stage renal disease (CrCl 15 mL/min or less): Data not available
Liver Dose Adjustments
- Mild (Child-Pugh A) hepatic impairment: No adjustment recommended.
- Moderate (Child-Pugh B) hepatic impairment: 300 mg orally 2 times daily
- Severe (Child-Pugh C) hepatic impairment: Data not available
Dose Adjustments
- Grade 3 or greater toxicity or an intolerable adverse reaction: Withhold therapy or reduce to the dose to 300 mg 2 times a day until symptoms improve; then resume therapy at 600 mg orally 2 times a day.
- Dose reduction below 300 mg orally 2 times a day is not recommended.
Administration advice:
- This drug should be taken with food.
- Swallow tablets whole; do not divide, crush, or chew.
- If a dose is missed it should be taken as soon as it is remembered prior to the next scheduled dose; do not take 2 doses together to make up for a missed dose.
Side Effects
The Most Common
- extreme tiredness
- arm, leg, hand, or foot pain
- arm, leg, hand, or foot pain
- rash
- blood in urine
- fever, rapid and/or shallow breathing, or cough
- chest pain or feeling of pressure in the chest
- seizures
- severe ongoing nausea or diarrhea;
- painful or difficult urination;
- blood in your urine;
- severe headache, blurred vision, pounding in your neck or ears;
- slow heart rate, weak pulse, fainting, slow breathing (breathing may stop);
- signs of a blood clot in the lung–chest pain, sudden cough, wheezing, rapid breathing, coughing up blood; or
- signs of a lung infection–fever, chills, cough with mucus, chest pain, shortness of breath.
More common
- Black, tarry stools
- bleeding gums
- blood in the urine
- bloody nose
- blurred vision
- coughing or spitting up blood
- difficulty in breathing or swallowing
- dizziness
- frequent urination
- headache
- increased menstrual flow or vaginal bleeding
- lower abdominal or stomach cramping
- nausea and vomiting
- nervousness
- nosebleeds
- painful urination
- paralysis
- pounding in the ears
- prolonged bleeding from cuts
- red or dark brown urine
- red or black, tarry stools
- slow, fast, or irregular heartbeat
- vomiting of blood or material that looks like coffee grounds
- unusual bleeding or bruising
Rare
- Blood in the urine
- chest pain or discomfort
- pain in the shoulders, arms, jaw, or neck
- painful or difficult urination
- seizures
- sweating
- trouble breathing
- Constipation
- decreased appetite
- increased weight
- pain in the arms or legs
- rash
- unusual tiredness or weakness
- Chest pain or tightness
- cough
- fever or chills
- muscle or bone pain
- sneezing
- sore throat
Drug Interaction
| DRUG | INTERACTION |
|---|---|
| Abametapir | The serum concentration of Darolutamide can be increased when it is combined with Abametapir. |
| Abemaciclib | The serum concentration of Abemaciclib can be increased when it is combined with Darolutamide. |
| Abrocitinib | The serum concentration of Darolutamide can be increased when it is combined with Abrocitinib. |
| Adenine | The metabolism of Darolutamide can be decreased when combined with Adenine. |
| Afatinib | The serum concentration of Afatinib can be increased when it is combined with Darolutamide. |
| Alectinib | Alectinib may decrease the excretion rate of Darolutamide which could result in a higher serum level. |
| Allopurinol | The serum concentration of Allopurinol can be increased when it is combined with Darolutamide. |
| Alpelisib | The serum concentration of Alpelisib can be increased when it is combined with Darolutamide. |
| Ambrisentan | The serum concentration of Darolutamide can be increased when it is combined with Ambrisentan. |
| Amiodarone | The serum concentration of Darolutamide can be increased when it is combined with Amiodarone. |
| Amitriptyline | The metabolism of Darolutamide can be decreased when combined with Amitriptyline. |
| Amprenavir | The serum concentration of Darolutamide can be increased when it is combined with Amprenavir. |
| Apalutamide | The serum concentration of Darolutamide can be decreased when it is combined with Apalutamide. |
| Apixaban | The serum concentration of Apixaban can be increased when it is combined with Darolutamide. |
| Aprepitant | The metabolism of Darolutamide can be decreased when combined with Aprepitant. |
| Arsenic trioxide | The serum concentration of Darolutamide can be increased when it is combined with Arsenic trioxide. |
| Articaine | The risk or severity of methemoglobinemia can be increased when Darolutamide is combined with Articaine. |
| Asciminib | The serum concentration of Darolutamide can be increased when it is combined with Asciminib. |
| Asunaprevir | The serum concentration of Darolutamide can be increased when it is combined with Asunaprevir. |
| Atazanavir | The serum concentration of Darolutamide can be increased when it is combined with Atazanavir. |
| Atogepant | The serum concentration of Atogepant can be increased when it is combined with Darolutamide. |
| Atorvastatin | The excretion of Atorvastatin can be decreased when combined with Darolutamide. |
| Avanafil | The serum concentration of Avanafil can be increased when it is combined with Darolutamide. |
| Avatrombopag | Avatrombopag may decrease the excretion rate of Darolutamide which could result in a higher serum level. |
| Axitinib | The serum concentration of Axitinib can be increased when it is combined with Darolutamide. |
| Beclomethasone | Beclomethasone dipropionate may decrease the excretion rate of Darolutamide which could result in a higher serum level. |
| Belantamab mafodotin | The serum concentration of Belantamab mafodotin can be increased when it is combined with Darolutamide. |
| Belinostat | The serum concentration of Darolutamide can be increased when it is combined with Belinostat. |
| Belumosudil | Belumosudil may decrease the excretion rate of Darolutamide which could result in a higher serum level. |
| Bempedoic acid | The excretion of Bempedoic acid can be decreased when combined with Darolutamide. |
| Bendamustine | The serum concentration of Bendamustine can be increased when it is combined with Darolutamide. |
| Benzocaine | The risk or severity of methemoglobinemia can be increased when Darolutamide is combined with Benzocaine. |
| Benzyl alcohol | The risk or severity of methemoglobinemia can be increased when Darolutamide is combined with Benzyl alcohol. |
| Benzylpenicillin | The excretion of Benzylpenicillin can be decreased when combined with Darolutamide. |
| Berotralstat | The serum concentration of Berotralstat can be increased when it is combined with Darolutamide. |
| Betrixaban | The serum concentration of Darolutamide can be increased when it is combined with Betrixaban. |
| Bexarotene | The serum concentration of Darolutamide can be decreased when it is combined with Bexarotene. |
| Binimetinib | The serum concentration of Binimetinib can be increased when it is combined with Darolutamide. |
| Bisoprolol | The serum concentration of Darolutamide can be increased when it is combined with Bisoprolol. |
| Boceprevir | The serum concentration of Darolutamide can be increased when it is combined with Boceprevir. |
| Bortezomib | The serum concentration of Bortezomib can be increased when it is combined with Darolutamide. |
| Bosentan | The serum concentration of Darolutamide can be decreased when it is combined with Bosentan. |
| Bosutinib | The serum concentration of Bosutinib can be increased when it is combined with Darolutamide. |
| Brentuximab vedotin | The serum concentration of Brentuximab vedotin can be increased when it is combined with Darolutamide. |
| Brigatinib | The serum concentration of Brigatinib can be increased when it is combined with Darolutamide. |
| Brincidofovir | The serum concentration of Brincidofovir can be increased when it is combined with Darolutamide. |
| Bupivacaine | The risk or severity of methemoglobinemia can be increased when Darolutamide is combined with Bupivacaine. |
| Buprenorphine | Buprenorphine may decrease the excretion rate of Darolutamide which could result in a higher serum level. |
| Butacaine | The risk or severity of methemoglobinemia can be increased when Darolutamide is combined with Butacaine. |
| Butamben | The risk or severity of methemoglobinemia can be increased when Darolutamide is combined with Butamben. |
| Cabazitaxel | Cabazitaxel may decrease the excretion rate of Darolutamide which could result in a higher serum level. |
| Cabergoline | The serum concentration of Cabergoline can be increased when it is combined with Darolutamide. |
| Caffeine | Caffeine may decrease the excretion rate of Darolutamide which could result in a higher serum level. |
| Canagliflozin | The serum concentration of Darolutamide can be increased when it is combined with Canagliflozin. |
| Cannabidiol | Cannabidiol may decrease the excretion rate of Darolutamide which could result in a higher serum level. |
| Capmatinib | The serum concentration of Darolutamide can be increased when it is combined with Capmatinib. |
| Capromab pendetide | Darolutamide may decrease effectiveness of Capromab pendetide as a diagnostic agent. |
| Capsaicin | The risk or severity of methemoglobinemia can be increased when Darolutamide is combined with Capsaicin. |
| Carbamazepine | The serum concentration of Darolutamide can be decreased when it is combined with Carbamazepine. |
| Carfilzomib | The serum concentration of Darolutamide can be increased when it is combined with Carfilzomib. |
| Carvedilol | The serum concentration of Darolutamide can be increased when it is combined with Carvedilol. |
| Caspofungin | The excretion of Caspofungin can be decreased when combined with Darolutamide. |
| Celecoxib | The serum concentration of Celecoxib can be increased when it is combined with Darolutamide. |
| Cenobamate | The serum concentration of Darolutamide can be decreased when it is combined with Cenobamate. |
| Ceritinib | The serum concentration of Ceritinib can be increased when it is combined with Darolutamide. |
| Cerivastatin | The serum concentration of Cerivastatin can be increased when it is combined with Darolutamide. |
| Chloroprocaine | The risk or severity of methemoglobinemia can be increased when Darolutamide is combined with Chloroprocaine. |
| Cholecystokinin | The excretion of Cholecystokinin can be decreased when combined with Darolutamide. |
| Cholesterol | Cholesterol may increase the excretion rate of Darolutamide which could result in a lower serum level and potentially a reduction in efficacy. |
| Cholic Acid | The excretion of Cholic Acid can be decreased when combined with Darolutamide. |
| Choline C 11 | Darolutamide may decrease effectiveness of Choline C 11 as a diagnostic agent. |
| Cinchocaine | The risk or severity of methemoglobinemia can be increased when Darolutamide is combined with Cinchocaine. |
| Ciprofloxacin | The metabolism of Darolutamide can be decreased when combined with Ciprofloxacin. |
| Cladribine | The serum concentration of Cladribine can be increased when it is combined with Darolutamide. |
| Clarithromycin | The serum concentration of Darolutamide can be increased when it is combined with Clarithromycin. |
| Clobazam | The serum concentration of Darolutamide can be increased when it is combined with Clobazam. |
| Clofarabine | Darolutamide may decrease the excretion rate of Clofarabine which could result in a higher serum level. |
| Clofazimine | Clofazimine may decrease the excretion rate of Darolutamide which could result in a higher serum level. |
| Clomifene | The serum concentration of Darolutamide can be increased when it is combined with Clomifene. |
| Clozapine | The metabolism of Darolutamide can be decreased when combined with Clozapine. |
| Cobicistat | The serum concentration of Darolutamide can be increased when it is combined with Cobicistat. |
| Cobimetinib | The serum concentration of Cobimetinib can be increased when it is combined with Darolutamide. |
| Cocaine | The risk or severity of methemoglobinemia can be increased when Darolutamide is combined with Cocaine. |
| Colchicine | The serum concentration of Darolutamide can be increased when it is combined with Colchicine. |
| Conivaptan | The serum concentration of Darolutamide can be increased when it is combined with Conivaptan. |
| Conjugated estrogens | The serum concentration of Conjugated estrogens can be increased when it is combined with Darolutamide. |
| Copanlisib | Darolutamide may decrease the excretion rate of Copanlisib which could result in a higher serum level. |
| Crizotinib | The metabolism of Darolutamide can be decreased when combined with Crizotinib. |
| Curcumin | The serum concentration of Darolutamide can be increased when it is combined with Curcumin. |
| Cyclosporine | The metabolism of Darolutamide can be decreased when combined with Cyclosporine. |
| Dabigatran etexilate | The serum concentration of Darolutamide can be increased when it is combined with Dabigatran etexilate. |
| Dabrafenib | The serum concentration of Dabrafenib can be increased when it is combined with Darolutamide. |
| Daclatasvir | Daclatasvir may decrease the excretion rate of Darolutamide which could result in a higher serum level. |
| Dacomitinib | The serum concentration of Dacomitinib can be increased when it is combined with Darolutamide. |
| Dactinomycin | Darolutamide may decrease the excretion rate of Dactinomycin which could result in a higher serum level. |
| Danazol | The serum concentration of Darolutamide can be increased when it is combined with Danazol. |
| Daptomycin | The serum concentration of Darolutamide can be increased when it is combined with Daptomycin. |
| Darbepoetin alfa | The risk or severity of Thrombosis can be increased when Darbepoetin alfa is combined with Darolutamide. |
| Darunavir | The serum concentration of Darolutamide can be increased when it is combined with Darunavir. |
| Dasabuvir | Dasabuvir may decrease the excretion rate of Darolutamide which could result in a higher serum level. |
| Dasatinib | The serum concentration of Dasatinib can be increased when it is combined with Darolutamide. |
| Daunorubicin | Darolutamide may decrease the excretion rate of Daunorubicin which could result in a higher serum level. |
| Deferasirox | The metabolism of Darolutamide can be decreased when combined with Deferasirox. |
| Delafloxacin | The serum concentration of Delafloxacin can be increased when it is combined with Darolutamide. |
| Delavirdine | The serum concentration of Darolutamide can be increased when it is combined with Delavirdine. |
| Desogestrel | The metabolism of Darolutamide can be increased when combined with Desogestrel. |
| Desvenlafaxine | The metabolism of Darolutamide can be decreased when combined with Desvenlafaxine. |
| Dexamethasone | The serum concentration of Darolutamide can be decreased when it is combined with Dexamethasone. |
| Dexamethasone | The serum concentration of Darolutamide can be decreased when it is combined with Dexamethasone acetate. |
| Diethylstilbestrol | Diethylstilbestrol may decrease the excretion rate of Darolutamide which could result in a higher serum level. |
| Diflunisal | The metabolism of Darolutamide can be decreased when combined with Diflunisal. |
| Digitoxin | The serum concentration of Digitoxin can be increased when it is combined with Darolutamide. |
| Digoxin | The serum concentration of Digoxin can be increased when it is combined with Darolutamide. |
| Diltiazem | The metabolism of Darolutamide can be decreased when combined with Diltiazem. |
| Dinoprostone | The excretion of Dinoprostone can be decreased when combined with Darolutamide. |
| Diosmin | The serum concentration of Darolutamide can be increased when it is combined with Diosmin. |
| Diphenhydramine | The risk or severity of methemoglobinemia can be increased when Darolutamide is combined with Diphenhydramine. |
| Docetaxel | The excretion of Docetaxel can be decreased when combined with Darolutamide. |
| Dolutegravir | The serum concentration of Dolutegravir can be increased when it is combined with Darolutamide. |
| Donepezil | The serum concentration of Donepezil can be increased when it is combined with Darolutamide. |
| Doxorubicin | Darolutamide may decrease the excretion rate of Doxorubicin which could result in a higher serum level. |
| Dronedarone | The metabolism of Darolutamide can be decreased when combined with Dronedarone. |
| Duvelisib | The serum concentration of Duvelisib can be increased when it is combined with Darolutamide. |
| Dyclonine | The risk or severity of methemoglobinemia can be increased when Darolutamide is combined with Dyclonine. |
| Echinacea | The serum concentration of Darolutamide can be decreased when it is combined with Echinacea. |
| Econazole | The serum concentration of Darolutamide can be increased when it is combined with Econazole. |
| Edoxaban | The serum concentration of Darolutamide can be increased when it is combined with Edoxaban. |
| Efavirenz | The serum concentration of Darolutamide can be decreased when it is combined with Efavirenz. |
| Elagolix | The serum concentration of Darolutamide can be increased when it is combined with Elagolix. |
| Elbasvir | Elbasvir may decrease the excretion rate of Darolutamide which could result in a higher serum level. |
| Eliglustat | The serum concentration of Darolutamide can be increased when it is combined with Eliglustat. |
| Eltrombopag | Eltrombopag may decrease the excretion rate of Darolutamide which could result in a higher serum level. |
| Eluxadoline | The serum concentration of Eluxadoline can be increased when it is combined with Darolutamide. |
| Elvitegravir | The serum concentration of Darolutamide can be increased when it is combined with Elvitegravir. |
| Enalapril | The excretion of Enalapril can be decreased when combined with Darolutamide. |
| Enasidenib | The serum concentration of Enasidenib can be increased when it is combined with Darolutamide. |
| Enfortumab vedotin | The serum concentration of Enfortumab vedotin can be increased when it is combined with Darolutamide. |
| Entrectinib | The serum concentration of Darolutamide can be increased when it is combined with Entrectinib. |
| Enzalutamide | The serum concentration of Darolutamide can be decreased when it is combined with Enzalutamide. |
| Erdafitinib | The serum concentration of Darolutamide can be increased when it is combined with Erdafitinib. |
| Ergotamine | The serum concentration of Darolutamide can be increased when it is combined with Ergotamine. |
| Erlotinib | Erlotinib may decrease the excretion rate of Darolutamide which could result in a higher serum level. |
| Ertugliflozin | The serum concentration of Ertugliflozin can be increased when it is combined with Darolutamide. |
| Erythromycin | The metabolism of Darolutamide can be decreased when combined with Erythromycin. |
| Erythropoietin | The risk or severity of Thrombosis can be increased when Erythropoietin is combined with Darolutamide. |
| Estradiol | Estradiol may decrease the excretion rate of Darolutamide which could result in a higher serum level. |
| Estradiol acetate | Estradiol acetate may decrease the excretion rate of Darolutamide which could result in a higher serum level. |
| Estradiol benzoate | Estradiol benzoate may decrease the excretion rate of Darolutamide which could result in a higher serum level. |
| Estradiol cypionate | Estradiol cypionate may decrease the excretion rate of Darolutamide which could result in a higher serum level. |
| Estradiol dienanthate | Estradiol dienanthate may decrease the excretion rate of Darolutamide which could result in a higher serum level. |
| Estradiol valerate | Estradiol valerate may decrease the excretion rate of Darolutamide which could result in a higher serum level. |
| Ethinylestradiol | The metabolism of Darolutamide can be increased when combined with Ethinylestradiol. |
| Ethyl chloride | The risk or severity of methemoglobinemia can be increased when Darolutamide is combined with Ethyl chloride. |
| Etidocaine | The risk or severity of methemoglobinemia can be increased when Darolutamide is combined with Etidocaine. |
| Etoposide | The serum concentration of Etoposide can be increased when it is combined with Darolutamide. |
| Etravirine | The serum concentration of Darolutamide can be decreased when it is combined with Etravirine. |
| Everolimus | The serum concentration of Darolutamide can be increased when it is combined with Everolimus. |
| Ezetimibe | The serum concentration of Ezetimibe can be increased when it is combined with Darolutamide. |
| Favipiravir | The serum concentration of Darolutamide can be increased when it is combined with Favipiravir. |
| Febuxostat | The excretion of Darolutamide can be decreased when combined with Febuxostat. |
| Fedratinib | Fedratinib may decrease the excretion rate of Darolutamide which could result in a higher serum level. |
| Fexofenadine | The serum concentration of Darolutamide can be increased when it is combined with Fexofenadine. |
| Flibanserin | The serum concentration of Darolutamide can be increased when it is combined with Flibanserin. |
| Fluconazole | The metabolism of Darolutamide can be decreased when combined with Fluconazole. |
| Flunitrazepam | The metabolism of Darolutamide can be decreased when combined with Flunitrazepam. |
| Fluorouracil | The serum concentration of Fluorouracil can be increased when it is combined with Darolutamide. |
| Flurbiprofen | The metabolism of Darolutamide can be decreased when combined with Flurbiprofen. |
| Fluvastatin | The excretion of Fluvastatin can be decreased when combined with Darolutamide. |
| Fluvoxamine | The metabolism of Darolutamide can be decreased when combined with Fluvoxamine. |
| Folic acid | The serum concentration of Folic acid can be increased when it is combined with Darolutamide. |
| Fosnetupitant | The metabolism of Darolutamide can be decreased when combined with Fosnetupitant. |
| Fosphenytoin | The serum concentration of Darolutamide can be decreased when it is combined with Fosphenytoin. |
| Fostamatinib | Fostamatinib may decrease the excretion rate of Darolutamide which could result in a higher serum level. |
| Fostemsavir | The serum concentration of Fostemsavir can be increased when it is combined with Darolutamide. |
| Fusidic acid | The metabolism of Darolutamide can be decreased when combined with Fusidic acid. |
| Futibatinib | The serum concentration of Futibatinib can be increased when it is combined with Darolutamide. |
| Gadoxetic acid | The excretion of Gadoxetic acid can be decreased when combined with Darolutamide. |
| Gallium Ga-68 | Darolutamide may increase effectiveness of Gallium Ga-68 gozetotide as a diagnostic agent. |
| Gefitinib | The serum concentration of Gefitinib can be increased when it is combined with Darolutamide. |
| Gemcitabine | The serum concentration of Gemcitabine can be increased when it is combined with Darolutamide. |
| Gemfibrozil | The metabolism of Darolutamide can be decreased when combined with Gemfibrozil. |
| Gilteritinib | Gilteritinib may decrease the excretion rate of Darolutamide which could result in a higher serum level. |
| Glasdegib | The serum concentration of Glasdegib can be increased when it is combined with Darolutamide. |
| Glecaprevir | The serum concentration of Glecaprevir can be increased when it is combined with Darolutamide. |
| Glyburide | The serum concentration of Glyburide can be increased when it is combined with Darolutamide. |
| Grazoprevir | Grazoprevir may decrease the excretion rate of Darolutamide which could result in a higher serum level. |
| Haloperidol | The serum concentration of Haloperidol can be increased when it is combined with Darolutamide. |
| Idelalisib | The serum concentration of Idelalisib can be increased when it is combined with Darolutamide. |
| Imatinib | The serum concentration of Imatinib can be increased when it is combined with Darolutamide. |
| Imipramine | The serum concentration of Imipramine can be increased when it is combined with Darolutamide. |
| Indacaterol | The serum concentration of Darolutamide can be increased when it is combined with Indacaterol. |
| Indinavir | The serum concentration of Darolutamide can be increased when it is combined with Indinavir. |
| Indomethacin | The metabolism of Darolutamide can be decreased when combined with Indomethacin. |
| Inotuzumab | The serum concentration of Inotuzumab ozogamicin can be increased when it is combined with Darolutamide. |
| Irinotecan | Darolutamide may decrease the excretion rate of Irinotecan which could result in a higher serum level. |
| Isavuconazole | The serum concentration of Darolutamide can be increased when it is combined with Isavuconazole. |
| Isavuconazonium | The serum concentration of Darolutamide can be increased when it is combined with Isavuconazonium. |
| Isoniazid | The metabolism of Darolutamide can be decreased when combined with Isoniazid. |
| Isradipine | The metabolism of Darolutamide can be decreased when combined with Isradipine. |
| Istradefylline | Istradefylline may decrease the excretion rate of Darolutamide which could result in a higher serum level. |
| Itraconazole | The serum concentration of Darolutamide can be increased when it is combined with Itraconazole. |
| Ivacaftor | The serum concentration of Darolutamide can be increased when it is combined with Ivacaftor. |
| Ivermectin | The serum concentration of Ivermectin can be increased when it is combined with Darolutamide. |
| Ivosidenib | The metabolism of Darolutamide can be increased when combined with Ivosidenib. |
| Ixabepilone | The serum concentration of Darolutamide can be increased when it is combined with Ixabepilone. |
| Ketoconazole | The serum concentration of Darolutamide can be increased when it is combined with Ketoconazole. |
| Lamivudine | The serum concentration of Lamivudine can be increased when it is combined with Darolutamide. |
| Lamotrigine | The metabolism of Darolutamide can be increased when combined with Lamotrigine. |
| Lansoprazole | Lansoprazole may decrease the excretion rate of Darolutamide which could result in a higher serum level. |
| Lapatinib | The serum concentration of Darolutamide can be increased when it is combined with Lapatinib. |
| Larotrectinib | The serum concentration of Larotrectinib can be increased when it is combined with Darolutamide. |
| Lasmiditan | The serum concentration of Darolutamide can be increased when it is combined with Lasmiditan. |
| Ledipasvir | Ledipasvir may decrease the excretion rate of Darolutamide which could result in a higher serum level. |
| Lefamulin | The serum concentration of Darolutamide can be increased when it is combined with Lefamulin. |
| Leflunomide | The serum concentration of Leflunomide can be increased when it is combined with Darolutamide. |
| Lemborexant | The serum concentration of Darolutamide can be increased when it is combined with Lemborexant. |
| Lenvatinib | The serum concentration of Lenvatinib can be increased when it is combined with Darolutamide. |
| Letermovir | Letermovir may decrease the excretion rate of Darolutamide which could result in a higher serum level. |
| Levobupivacaine | The risk or severity of methemoglobinemia can be increased when Darolutamide is combined with Levobupivacaine. |
| Levoketoconazole | The serum concentration of Darolutamide can be increased when it is combined with Levoketoconazole. |
| Levosalbutamol | The excretion of Levosalbutamol can be decreased when combined with Darolutamide. |
| Lidocaine | The risk or severity of methemoglobinemia can be increased when Darolutamide is combined with Lidocaine. |
| Linagliptin | The metabolism of Darolutamide can be decreased when combined with Linagliptin. |
| Liothyronine | The excretion of Liothyronine can be decreased when combined with Darolutamide. |
| Liotrix | The excretion of Liotrix can be decreased when combined with Darolutamide. |
| Lomitapide | The serum concentration of Darolutamide can be increased when it is combined with Lomitapide. |
| Lonafarnib | The serum concentration of Darolutamide can be increased when it is combined with Lonafarnib. |
| Loncastuximab | The serum concentration of Loncastuximab tesirine can be increased when it is combined with Darolutamide. |
| Loperamide | The serum concentration of Darolutamide can be increased when it is combined with Loperamide. |
| Lopinavir | The serum concentration of Darolutamide can be increased when it is combined with Lopinavir. |
| Lovastatin | The metabolism of Darolutamide can be decreased when combined with Lovastatin. |
| Loxapine | The serum concentration of Darolutamide can be increased when it is combined with Loxapine. |
| Lumacaftor | The serum concentration of Darolutamide can be decreased when it is combined with Lumacaftor. |
| Lusutrombopag | The serum concentration of Lusutrombopag can be increased when it is combined with Darolutamide. |
| Mannitol | The serum concentration of Darolutamide can be increased when it is combined with Mannitol. |
| Maribavir | Maribavir may decrease the excretion rate of Darolutamide which could result in a higher serum level. |
| Mavacamten | The serum concentration of Darolutamide can be decreased when it is combined with Mavacamten. |
| Mefenamic acid | The metabolism of Darolutamide can be decreased when combined with Mefenamic acid. |
| Mefloquine | The serum concentration of Darolutamide can be increased when it is combined with Mefloquine. |
| Meloxicam | The risk or severity of methemoglobinemia can be increased when Darolutamide is combined with Meloxicam. |
| Mepivacaine | The risk or severity of methemoglobinemia can be increased when Darolutamide is combined with Mepivacaine. |
| Methimazole | The serum concentration of Darolutamide can be increased when it is combined with Methimazole. |
| Methotrexate | The serum concentration of Methotrexate can be increased when it is combined with Darolutamide. |
| Methoxy | The risk or severity of Thrombosis can be increased when Methoxy polyethylene glycol-epoetin beta is combined with Darolutamide. |
| Methylene blue | The serum concentration of Darolutamide can be increased when it is combined with Methylene blue. |
| Metreleptin | The metabolism of Darolutamide can be increased when combined with Metreleptin. |
| Miconazole | The metabolism of Darolutamide can be decreased when combined with Miconazole. |
| Midostaurin | The serum concentration of Darolutamide can be decreased when it is combined with Midostaurin. |
| Mifepristone | The serum concentration of Darolutamide can be increased when it is combined with Mifepristone. |
| Milnacipran | The metabolism of Darolutamide can be decreased when combined with Milnacipran. |
| Mirabegron | The serum concentration of Darolutamide can be increased when it is combined with Mirabegron. |
| Mitapivat | The metabolism of Darolutamide can be increased when combined with Mitapivat. |
| Mitotane | The serum concentration of Darolutamide can be decreased when it is combined with Mitotane. |
| Mitoxantrone | Darolutamide may decrease the excretion rate of Mitoxantrone which could result in a higher serum level. |
| Modafinil | The serum concentration of Darolutamide can be decreased when it is combined with Modafinil. |
| Morphine | The serum concentration of Darolutamide can be increased when it is combined with Morphine. |
| Mycophenolate | The serum concentration of Mycophenolate mofetil can be increased when it is combined with Darolutamide. |
| Nafcillin | The serum concentration of Darolutamide can be decreased when it is combined with Nafcillin. |
| Naloxone | The serum concentration of Darolutamide can be increased when it is combined with Naloxone. |
| Nefazodone | The serum concentration of Darolutamide can be increased when it is combined with Nefazodone. |
| Nelfinavir | The serum concentration of Darolutamide can be increased when it is combined with Nelfinavir. |
| Neratinib | The serum concentration of Darolutamide can be increased when it is combined with Neratinib. |
| Netupitant | The metabolism of Darolutamide can be decreased when combined with Netupitant. |
| Nicardipine | The metabolism of Darolutamide can be decreased when combined with Nicardipine. |
| Nilotinib | The serum concentration of Darolutamide can be increased when it is combined with Nilotinib. |
| Nilvadipine | The metabolism of Darolutamide can be decreased when combined with Nilvadipine. |
| Nintedanib | The serum concentration of Darolutamide can be increased when it is combined with Nintedanib. |
| Nitrofurantoin | The serum concentration of Nitrofurantoin can be increased when it is combined with Darolutamide. |
| Norgestimate | The serum concentration of Darolutamide can be increased when it is combined with Norgestimate. |
| Nortriptyline | The serum concentration of Nortriptyline can be increased when it is combined with Darolutamide. |
| Novobiocin | Novobiocin may decrease the excretion rate of Darolutamide which could result in a higher serum level. |
| Omadacycline | The serum concentration of Darolutamide can be increased when it is combined with Omadacycline. |
| Ombitasvir | The serum concentration of Ombitasvir can be increased when it is combined with Darolutamide. |
| Omeprazole | Omeprazole may decrease the excretion rate of Darolutamide which could result in a higher serum level. |
| Osimertinib | The serum concentration of Osimertinib can be increased when it is combined with Darolutamide. |
| Oteseconazole | The serum concentration of Darolutamide can be increased when it is combined with Oteseconazole. |
| Ouabain | The excretion of Ouabain can be decreased when combined with Darolutamide. |
| Oxaliplatin | Darolutamide may decrease the excretion rate of Oxaliplatin which could result in a higher serum level. |
| Oxetacaine | The risk or severity of methemoglobinemia can be increased when Darolutamide is combined with Oxetacaine. |
| Oxybuprocaine | The risk or severity of methemoglobinemia can be increased when Darolutamide is combined with Oxybuprocaine. |
| Ozanimod | Darolutamide may decrease the excretion rate of Ozanimod which could result in a higher serum level. |
| Paclitaxel | The excretion of Paclitaxel can be decreased when combined with Darolutamide. |
| Pacritinib | The serum concentration of Darolutamide can be increased when it is combined with Pacritinib. |
| Palbociclib | The serum concentration of Palbociclib can be increased when it is combined with Darolutamide. |
| Paliperidone | The serum concentration of Darolutamide can be increased when it is combined with Paliperidone. |
| Panobinostat | The serum concentration of Panobinostat can be increased when it is combined with Darolutamide. |
| Pantoprazole | Pantoprazole may decrease the excretion rate of Darolutamide which could result in a higher serum level. |
| Paritaprevir | Paritaprevir may decrease the excretion rate of Darolutamide which could result in a higher serum level. |
| Pazopanib | The serum concentration of Pazopanib can be increased when it is combined with Darolutamide. |
| Peginesatide | The risk or severity of Thrombosis can be increased when Peginesatide is combined with Darolutamide. |
| Penicillamine | The excretion of Penicillamine can be decreased when combined with Darolutamide. |
| Pentobarbital | The serum concentration of Darolutamide can be decreased when it is combined with Pentobarbital. |
| Pexidartinib | The metabolism of Darolutamide can be decreased when combined with Pexidartinib. |
| Phenobarbital | The serum concentration of Darolutamide can be decreased when it is combined with Phenobarbital. |
| Phenol | The risk or severity of methemoglobinemia can be increased when Darolutamide is combined with Phenol. |
| Phenytoin | The serum concentration of Darolutamide can be decreased when it is combined with Phenytoin. |
| Pibrentasvir | The serum concentration of Pibrentasvir can be increased when it is combined with Darolutamide. |
| Piflufolastat F 18 | Darolutamide may decrease effectiveness of Piflufolastat F 18 as a diagnostic agent. |
| Pitavastatin | The serum concentration of Pitavastatin can be increased when it is combined with Darolutamide. |
| Pitolisant | The serum concentration of Darolutamide can be decreased when it is combined with Pitolisant. |
| Pomalidomide | The serum concentration of Pomalidomide can be increased when it is combined with Darolutamide. |
| Ponatinib | The serum concentration of Ponatinib can be increased when it is combined with Darolutamide. |
| Posaconazole | The serum concentration of Darolutamide can be increased when it is combined with Posaconazole. |
| Pralatrexate | Darolutamide may decrease the excretion rate of Pralatrexate which could result in a higher serum level. |
| Pralsetinib | The serum concentration of Pralsetinib can be increased when it is combined with Darolutamide. |
| Pramocaine | The risk or severity of methemoglobinemia can be increased when Darolutamide is combined with Pramocaine. |
| Pravastatin | The serum concentration of Pravastatin can be increased when it is combined with Darolutamide. |
| Prazosin | The serum concentration of Prazosin can be increased when it is combined with Darolutamide. |
| Prednisolone | The serum concentration of Prednisolone phosphate can be increased when it is combined with Darolutamide. |
| Prilocaine | The risk or severity of methemoglobinemia can be increased when Darolutamide is combined with Prilocaine. |
| Primaquine | The metabolism of Darolutamide can be decreased when combined with Primaquine. |
| Primidone | The serum concentration of Darolutamide can be decreased when it is combined with Primidone. |
| Probenecid | The metabolism of Darolutamide can be decreased when combined with Probenecid. |
| Procaine | The risk or severity of methemoglobinemia can be increased when Darolutamide is combined with Procaine. |
| Progesterone | Progesterone may decrease the excretion rate of Darolutamide which could result in a higher serum level. |
| Propafenone | The serum concentration of Darolutamide can be increased when it is combined with Propafenone. |
| Proparacaine | The risk or severity of methemoglobinemia can be increased when Darolutamide is combined with Proparacaine. |
| Propofol | The metabolism of Darolutamide can be decreased when combined with Propofol. |
| Propoxycaine | The risk or severity of methemoglobinemia can be increased when Darolutamide is combined with Propoxycaine. |
| Quinidine | The serum concentration of Darolutamide can be increased when it is combined with Quinidine. |
| Quinine | The serum concentration of Darolutamide can be increased when it is combined with Quinine. |
| Rabeprazole | Rabeprazole may decrease the excretion rate of Darolutamide which could result in a higher serum level. |
| Raloxifene | The serum concentration of Raloxifene can be increased when it is combined with Darolutamide. |
| Ranolazine | The serum concentration of Darolutamide can be increased when it is combined with Ranolazine. |
| Regorafenib | Regorafenib may decrease the excretion rate of Darolutamide which could result in a higher serum level. |
| Relugolix | The serum concentration of Darolutamide can be increased when it is combined with Relugolix. |
| Repaglinide | The excretion of Repaglinide can be decreased when combined with Darolutamide. |
| Reserpine | The serum concentration of Darolutamide can be increased when it is combined with Reserpine. |
| Revefenacin | Darolutamide may decrease the excretion rate of Revefenacin which could result in a higher serum level. |
| Ribociclib | The serum concentration of Darolutamide can be increased when it is combined with Ribociclib. |
| Rifampicin | The serum concentration of Darolutamide can be decreased when it is combined with Rifampicin. |
| Rifamycin | The serum concentration of Darolutamide can be decreased when it is combined with Rifamycin. |
| Rifapentine | The serum concentration of Darolutamide can be decreased when it is combined with Rifapentine. |
| Rilpivirine | Rilpivirine may decrease the excretion rate of Darolutamide which could result in a higher serum level. |
| Riluzole | The serum concentration of Riluzole can be increased when it is combined with Darolutamide. |
| Rimegepant | The serum concentration of Rimegepant can be increased when it is combined with Darolutamide. |
| Rimexolone | The serum concentration of Darolutamide can be decreased when it is combined with Rimexolone. |
| Riociguat | The serum concentration of Riociguat can be increased when it is combined with Darolutamide. |
| Ripretinib | The serum concentration of Ripretinib can be increased when it is combined with Darolutamide. |
| Ritonavir | The serum concentration of Darolutamide can be increased when it is combined with Ritonavir. |
| Rivaroxaban | The serum concentration of Rivaroxaban can be increased when it is combined with Darolutamide. |
| Rolapitant | Rolapitant may decrease the excretion rate of Darolutamide which could result in a higher serum level. |
| Romidepsin | The serum concentration of Romidepsin can be increased when it is combined with Darolutamide. |
| Ropivacaine | The risk or severity of methemoglobinemia can be increased when Darolutamide is combined with Ropivacaine. |
| Rosuvastatin | The serum concentration of Rosuvastatin can be increased when it is combined with Darolutamide. |
| Roxadustat | The serum concentration of Darolutamide can be increased when it is combined with Roxadustat. |
| Rucaparib | The serum concentration of Rucaparib can be increased when it is combined with Darolutamide. |
| Safinamide | Safinamide may decrease the excretion rate of Darolutamide which could result in a higher serum level. |
| Sapropterin | The serum concentration of Darolutamide can be increased when it is combined with Sapropterin. |
| Saquinavir | The serum concentration of Darolutamide can be increased when it is combined with Saquinavir. |
| Sarecycline | The serum concentration of Darolutamide can be increased when it is combined with Sarecycline. |
| Satralizumab | The serum concentration of Darolutamide can be decreased when it is combined with Satralizumab. |
| Selexipag | The serum concentration of Darolutamide can be increased when it is combined with Selexipag. |
| Selumetinib | The serum concentration of Selumetinib can be increased when it is combined with Darolutamide. |
| Sildenafil | The serum concentration of Darolutamide can be increased when it is combined with Sildenafil. |
| Silodosin | The serum concentration of Darolutamide can be increased when it is combined with Silodosin. |
| Simeprevir | The serum concentration of Simeprevir can be increased when it is combined with Darolutamide. |
| Simvastatin | The serum concentration of Darolutamide can be increased when it is combined with Simvastatin. |
| Sincalide | The excretion of Sincalide can be decreased when combined with Darolutamide. |
| Sirolimus | The serum concentration of Sirolimus can be increased when it is combined with Darolutamide. |
| Sitagliptin | The serum concentration of Darolutamide can be increased when it is combined with Sitagliptin. |
| Sodium | The metabolism of Darolutamide can be decreased when combined with Sodium aurothiomalate. |
| Sofosbuvir | The serum concentration of Sofosbuvir can be increased when it is combined with Darolutamide. |
| Somatrogon | The metabolism of Darolutamide can be increased when combined with Somatrogon. |
| Sorafenib | The serum concentration of Sorafenib can be increased when it is combined with Darolutamide. |
| Sotagliflozin | Sotagliflozin may decrease the excretion rate of Darolutamide which could result in a higher serum level. |
| Sotorasib | The serum concentration of Darolutamide can be decreased when it is combined with Sotorasib. |
| St. John’s Wort | The serum concentration of Darolutamide can be decreased when it is combined with St. John’s Wort. |
| Stiripentol | The serum concentration of Darolutamide can be increased when it is combined with Stiripentol. |
| Sulfasalazine | The serum concentration of Sulfasalazine can be increased when it is combined with Darolutamide. |
| Sumatriptan | The serum concentration of Sumatriptan can be increased when it is combined with Darolutamide. |
| Sunitinib | Sunitinib may decrease the excretion rate of Darolutamide which could result in a higher serum level. |
| Suvorexant | The serum concentration of Darolutamide can be increased when it is combined with Suvorexant. |
| Tacrolimus | The serum concentration of Darolutamide can be increased when it is combined with Tacrolimus. |
| Tafamidis | The serum concentration of Darolutamide can be increased when it is combined with Tafamidis. |
| Talazoparib | The serum concentration of Talazoparib can be increased when it is combined with Darolutamide. |
| Tamoxifen | The serum concentration of Tamoxifen can be increased when it is combined with Darolutamide. |
| Taurocholic acid | Taurocholic acid may decrease the excretion rate of Darolutamide which could result in a higher serum level. |
| Tazemetostat | The serum concentration of Tazemetostat can be increased when it is combined with Darolutamide. |
| Technetium | The excretion of Technetium Tc-99m mebrofenin can be decreased when combined with Darolutamide. |
| Technetium | The serum concentration of Darolutamide can be increased when it is combined with Technetium Tc-99m sestamibi. |
| Tegaserod | The serum concentration of Tegaserod can be increased when it is combined with Darolutamide. |
| Telaprevir | The serum concentration of Darolutamide can be increased when it is combined with Telaprevir. |
| Telithromycin | The serum concentration of Darolutamide can be increased when it is combined with Telithromycin. |
| Telmisartan | Telmisartan may decrease the excretion rate of Darolutamide which could result in a higher serum level. |
| Telotristat ethyl | The serum concentration of Darolutamide can be decreased when it is combined with Telotristat ethyl. |
| Temsirolimus | The serum concentration of Darolutamide can be increased when it is combined with Temsirolimus. |
| Teniposide | Darolutamide may decrease the excretion rate of Teniposide which could result in a higher serum level. |
| Tenofovir | The serum concentration of Tenofovir alafenamide can be increased when it is combined with Darolutamide. |
| Tenofovir disoproxil | The serum concentration of Darolutamide can be increased when it is combined with Tenofovir disoproxil. |
| Tepotinib | The serum concentration of Darolutamide can be increased when it is combined with Tepotinib. |
| Terfenadine | The serum concentration of Darolutamide can be increased when it is combined with Terfenadine. |
| Teriflunomide | The serum concentration of Teriflunomide can be increased when it is combined with Darolutamide. |
| Testosterone | The serum concentration of Testosterone can be increased when it is combined with Darolutamide. |
| Testosterone | Darolutamide may decrease the excretion rate of Testosterone cypionate which could result in a higher serum level. |
| Testosterone | Darolutamide may decrease the excretion rate of Testosterone enanthate which could result in a higher serum level. |
| Testosterone | The metabolism of Darolutamide can be increased when combined with Testosterone propionate. |
| Tetracaine | The risk or severity of methemoglobinemia can be increased when Darolutamide is combined with Tetracaine. |
| Tezacaftor | The serum concentration of Darolutamide can be increased when it is combined with Tezacaftor. |
| Ticagrelor | The serum concentration of Darolutamide can be increased when it is combined with Ticagrelor. |
| Tipranavir | The serum concentration of Darolutamide can be increased when it is combined with Tipranavir. |
| Tivozanib | Tivozanib may decrease the excretion rate of Darolutamide which could result in a higher serum level. |
| Tolvaptan | The serum concentration of Tolvaptan can be increased when it is combined with Darolutamide. |
| Topotecan | The serum concentration of Topotecan can be increased when it is combined with Darolutamide. |
| Torasemide | The excretion of Torasemide can be decreased when combined with Darolutamide. |
| Toremifene | The serum concentration of Darolutamide can be increased when it is combined with Toremifene. |
| Trastuzumab emtansine | The serum concentration of Trastuzumab emtansine can be increased when it is combined with Darolutamide. |
| Trilaciclib | Darolutamide may decrease the excretion rate of Trilaciclib which could result in a higher serum level. |
| Trimipramine | The serum concentration of Trimipramine can be increased when it is combined with Darolutamide. |
| Troleandomycin | The serum concentration of Darolutamide can be increased when it is combined with Troleandomycin. |
| Tucatinib | The serum concentration of Tucatinib can be increased when it is combined with Darolutamide. |
| Ubrogepant | The serum concentration of Ubrogepant can be increased when it is combined with Darolutamide. |
| Umbralisib | The serum concentration of Darolutamide can be increased when it is combined with Umbralisib. |
| Umeclidinium | The serum concentration of Darolutamide can be increased when it is combined with Umeclidinium. |
| Valproic acid | The metabolism of Darolutamide can be decreased when combined with Valproic acid. |
| Valsartan | The excretion of Valsartan can be decreased when combined with Darolutamide. |
| Vandetanib | Vandetanib may decrease the excretion rate of Darolutamide which could result in a higher serum level. |
| Vardenafil | The serum concentration of Darolutamide can be increased when it is combined with Vardenafil. |
| Velpatasvir | The serum concentration of Velpatasvir can be increased when it is combined with Darolutamide. |
| Vemurafenib | The serum concentration of Darolutamide can be increased when it is combined with Vemurafenib. |
| Venetoclax | The serum concentration of Venetoclax can be increased when it is combined with Darolutamide. |
| Venlafaxine | Venlafaxine may increase the excretion rate of Darolutamide which could result in a lower serum level and potentially a reduction in efficacy. |
| Verapamil | The metabolism of Darolutamide can be decreased when combined with Verapamil. |
| Viloxazine | The metabolism of Darolutamide can be decreased when combined with Viloxazine. |
| Vinblastine | The serum concentration of Vinblastine can be increased when it is combined with Darolutamide. |
| Vincristine | Darolutamide may decrease the excretion rate of Vincristine which could result in a higher serum level. |
| Vinflunine | The serum concentration of Vinflunine can be increased when it is combined with Darolutamide. |
| Vismodegib | Vismodegib may decrease the excretion rate of Darolutamide which could result in a higher serum level. |
| Voclosporin | The serum concentration of Darolutamide can be increased when it is combined with Voclosporin. |
| Vorapaxar | The serum concentration of Darolutamide can be increased when it is combined with Vorapaxar. |
| Voriconazole | The serum concentration of Darolutamide can be increased when it is combined with Voriconazole. |
| Voxilaprevir | The serum concentration of Voxilaprevir can be increased when it is combined with Darolutamide. |
| Zidovudine | The serum concentration of Zidovudine can be increased when it is combined with Darolutamide. |
| Zimelidine | The metabolism of Darolutamide can be decreased when combined with Zimelidine. |
| Ziprasidone | The metabolism of Darolutamide can be decreased when combined with Ziprasidone. |
| Zonisamide | The serum concentration of Darolutamide can be increased when it is combined with Zonisamide. |
Pregnancy and Lactation
AU TGA pregnancy category: D
US FDA pregnancy category: Not assigned.
Pregnancy
The safety and efficacy of this drug have not been established in females. Based on its mechanism of action, this drug can cause fetal harm and loss of pregnancy. Advise male patients with female partners of reproductive potential to use effective contraception during therapy and for 1 week after. Based on animal studies, this drug may impair fertility in males of reproductive potential.
Lactation
There are no adequate studies in women for determining infant risk when using this medication during breastfeeding. Weigh the potential benefits against the potential risks before taking this medication while breastfeeding.
How should this medicine be used?
Darolutamide comes as a tablet to take by mouth. It is usually taken with food twice a day. Take darolutamide at around the same time(s) every day. Follow the directions on your prescription label carefully, and ask your doctor or pharmacist to explain any part you do not understand. Take darolutamide exactly as directed. Do not take more or less of it or take it more often than prescribed by your doctor.
Swallow the tablets whole; do not split, chew, or crush them.
Your doctor may tell you to stop taking darolutamide for a short time or decrease your dose if you experience serious side effects during your treatment. Be sure to talk to your doctor about how you are feeling during your treatment with darolutamide.
If your doctor has prescribed another medication such as goserelin (Zoladex), histrelin (Supprelin LA, Vantas), leuprolide (Eligard, Lupron), or triptorelin (Trelstar) to treat your prostate cancer, you will need to continue receiving this medication during your treatment with darolutamide.
Continue to take darolutamide even if you feel well. Do not stop taking darolutamide without talking to your doctor. Ask your pharmacist or doctor for a copy of the manufacturer’s information for the patient.
What special precautions should I follow?
Before taking darolutamide,
- tell your doctor and pharmacist if you are allergic to darolutamide, any other medications, or any of the ingredients in darolutamide tablets. Ask your pharmacist for a list of the ingredients.
- tell your doctor and pharmacist what other prescription and nonprescription medications, vitamins, nutritional supplements, and herbal products you are taking or plan to take. Your doctor may need to change the doses of your medications or monitor you carefully for side effects.
- tell your doctor what herbal products you are taking, especially St. John’s Wort.
- tell your doctor if you have or have ever had kidney disease, liver disease, heart disease, high blood pressure, diabetes, high blood cholesterol or history of seizures.
- you should know that darolutamide is only for use in men. Women should not take this medication, especially if they are or may become pregnant or are breastfeeding. If taken by pregnant women, darolutamide may harm the fetus. If a pregnant woman takes darolutamide, she should call her doctor immediately. If your female partner is not pregnant but could become pregnant, you and your partner must use birth control during your treatment and for 1 week after your final dose.
- you should know that this medication may decrease fertility in men. However, you should not assume that your female partner cannot become pregnant during your treatment.
References
